Fed. Circ. Won't Eye Amgen Case But Disputes 'Sky Is Falling'

By Tiffany Hu (June 21, 2021, 8:06 PM EDT) -- The full Federal Circuit on Monday refused to revisit a decision that invalidated two of Amgen's patents on its cholesterol medication Repatha, though a panel of judges disputed the drugmaker's "sky is falling" approach in arguing that the ruling changed the law.

In a nonprecedential order, the full appeals court denied without comment Amgen's petition for en banc review of a panel ruling that found it would have taken undue experimentation to figure out the bounds of the claims in Amgen's patents, making them invalid for lack of enablement.

Other companies had backed Amgen as well, including GlaxoSmithKline PLC, which argued...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!